1
|
Charrier S. Le vécu des professionnels de recherche clinique. PSYCHO-ONCOLOGIE 2020. [DOI: 10.3166/pson-2020-0119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Parmi les missions du psychologue en en cancérologie, figure le soutien aux professionnels de santé. la demande peut être relayée par la responsable de service, ce qui fut le cas pour les attachés et techniciens du centre de recherche clinique. Il sera exposé ici les temps d’échanges et de réflexion réguliers animés par le psychologue qui ont soutenu les questionnements suivants : comment concilier les exigences de la recherche avec celles de la relation de soin ? Comment préserver le risque d’une fragmentation de l’identité professionnelle ? Comment la prise de parole sur soi peut-elle viser une reconnaissance des limites identitaires ?
Collapse
|
2
|
Rivera-Munoz P, Abramowski V, Jacquot S, André P, Charrier S, Lipson-Ruffert K, Fischer A, Galy A, Cavazzana M, de Villartay JP. Lymphopoiesis in transgenic mice over-expressing Artemis. Gene Ther 2015; 23:176-86. [PMID: 26361272 DOI: 10.1038/gt.2015.95] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2015] [Revised: 08/28/2015] [Accepted: 09/08/2015] [Indexed: 12/27/2022]
Abstract
Artemis is a factor of the non-homologous end joining pathway involved in DNA double-strand break repair that has a critical role in V(D)J recombination. Mutations in DCLRE1C/ARTEMIS gene result in radiosensitive severe combined immunodeficiency in humans owing to a lack of mature T and B cells. Given the known drawbacks of allogeneic hematopoietic stem cell transplantation (HSCT), gene therapy appears as a promising alternative for these patients. However, the safety of an unregulated expression of Artemis has to be established. We developed a transgenic mouse model expressing human Artemis under the control of the strong CMV early enhancer/chicken beta actin promoter through knock-in at the ROSA26 locus to analyze this issue. Transgenic mice present a normal development, maturation and function of T and B cells with no signs of lymphopoietic malignancies for up to 15 months. These results suggest that the over-expression of Artemis in mice (up to 40 times) has no deleterious effects in early and mature lymphoid cells and support the safety of gene therapy as a possible curative treatment for Artemis-deficient patients.
Collapse
Affiliation(s)
- P Rivera-Munoz
- Laboratory of Genome Dynamics in the Immune System (DGSI), INSERM UMR1163, Paris, France.,Paris-Descartes, Sorbonne Paris Cité University, Imagine Institute, Paris, France
| | - V Abramowski
- Laboratory of Genome Dynamics in the Immune System (DGSI), INSERM UMR1163, Paris, France.,Paris-Descartes, Sorbonne Paris Cité University, Imagine Institute, Paris, France
| | - S Jacquot
- Institut Clinique de la Souris, PHENOMIN, CNRS, INSERM, Université de Strasbourg, Illkirch, France
| | - P André
- Institut Clinique de la Souris, PHENOMIN, CNRS, INSERM, Université de Strasbourg, Illkirch, France
| | | | - K Lipson-Ruffert
- Service des Animaux Transgéaniques, UPS44, CNRS, Villejuif, France
| | - A Fischer
- Paris-Descartes, Sorbonne Paris Cité University, Imagine Institute, Paris, France.,Unité d'Immunologie et Hématologie Pédiatrique, AP/HP, Hôpital Necker-Enfants Malades, Paris, France.,Collège de France, Paris, France
| | | | - M Cavazzana
- Paris-Descartes, Sorbonne Paris Cité University, Imagine Institute, Paris, France.,Unité d'Immunologie et Hématologie Pédiatrique, AP/HP, Hôpital Necker-Enfants Malades, Paris, France
| | - J-P de Villartay
- Laboratory of Genome Dynamics in the Immune System (DGSI), INSERM UMR1163, Paris, France.,Paris-Descartes, Sorbonne Paris Cité University, Imagine Institute, Paris, France
| |
Collapse
|
3
|
Charrier S, Dupré L, Scaramuzza S, Jeanson-Leh L, Blundell MP, Danos O, Cattaneo F, Aiuti A, Eckenberg R, Thrasher AJ, Roncarolo MG, Galy A. Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients. Gene Ther 2006; 14:415-28. [PMID: 17051251 DOI: 10.1038/sj.gt.3302863] [Citation(s) in RCA: 84] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Gene therapy has been proposed as a potential treatment for Wiskott-Aldrich syndrome (WAS), a severe primary immune deficiency characterized by multiple hematopoietic-specific cellular defects. In order to develop an optimal lentiviral gene transfer cassette for this application, we compared the performance of several internal promoters in a variety of cell lineages from human WAS patients. Vectors using endogenous promoters derived from short (0.5 kb) or long (1.6 kb) 5' flanking sequences of the WAS gene, expressed the transgene in T, B, dendritic cells as well as CD34(+) progenitor cells, but functioned poorly in non-hematopoietic cells. Defects of T-cell proliferation and interleukin-2 production, and the cytoskeletal anomalies in WAS dendritic cells were also corrected. The levels of reconstitution were comparable to those obtained following transduction with similar lentiviral vectors incorporating constitutive PGK-1, EF1-alpha promoters or the spleen focus forming virus gammaretroviral LTR. Thus, native regulatory sequences target the expression of the therapeutic WAS transgene to the hematopoietic system, as is naturally the case for WAS, and are effective for correction of multiple cellular defects. These vectors may have significant advantages for clinical application in terms of natural gene regulation, and reduction in the potential for adverse mutagenic events.
Collapse
|
4
|
Charrier S, Stockholm D, Seye K, Opolon P, Taveau M, Gross DA, Bucher-Laurent S, Delenda C, Vainchenker W, Danos O, Galy A. A lentiviral vector encoding the human Wiskott–Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice. Gene Ther 2004; 12:597-606. [PMID: 15616597 DOI: 10.1038/sj.gt.3302440] [Citation(s) in RCA: 96] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Wiskott-Aldrich syndrome (WAS) is an immune deficiency with thrombopenia resulting from mutations in the WASP gene. This gene normally encodes the Wiskott-Aldrich syndrome protein (WASP), a major cytoskeletal regulator expressed in hematopoietic cells. Gene therapy is a promising option for the treatment of WAS, requiring that clinically applicable WASP gene transfer vectors demonstrate efficacy in preclinical studies. Here, we describe a self-inactivating HIV-1-derived lentiviral vector encoding human WASP and show that it effectively transduced bone marrow progenitor cells of WASP knockout (WKO) mice. Transplantation of these transduced cells into lethally irradiated WKO recipients led to stable expression of WASP and correction of immune, inflammatory and cytoskeletal defects. Splenic T-cell proliferation was restored, podosomes were reinstated on bone-marrow-derived dendritic cells and colon inflammation was reduced. This shows for the first time (a) that cytoskeletal defects can be corrected in WKO mice, (b) that human WASP is biologically active in mice and (c) that a lentiviral vector is effective to express human WASP in vivo over several months. These data support further development of such lentiviral vectors for the gene therapy of WAS.
Collapse
|
5
|
Charrier S, Feuvret L. [Patient education in oncology: Proceedings of the XX Congress of the French Society of Psycho-Oncology. 5-6 December 2003, Lyon, France]. Cancer Radiother 2004; 8:274-6. [PMID: 15450523 DOI: 10.1016/j.canrad.2004.03.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2004] [Revised: 03/19/2004] [Accepted: 03/19/2004] [Indexed: 10/26/2022]
Affiliation(s)
- S Charrier
- Centre d'oncologie et de radiothérapie de Chaumont-le-Bois, 17, avenue des Etats-Unis, 52000 Chaumont, France.
| | | |
Collapse
|
6
|
Charrier S, Chollet P, Bay JO, Curé H, Kwiatkowski F, Portefaix G, Communal Y, Bétail G, Plagne R, Chassagne J. Hematological recovery and peripheral blood progenitor cell mobilization after induction chemotherapy and GM-CSF plus G-CSF in breast cancer. Bone Marrow Transplant 2000; 25:705-10. [PMID: 10745254 DOI: 10.1038/sj.bmt.1702205] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
In order to determine the effect of GM-CSF plus G-CSF in combination in breast cancer patients receiving an effective induction regimen, we compared hematological recovery and peripheral blood progenitor cell (PBPC) mobilization according to colony-stimulating factor (CSF) support. Forty-three breast cancer patients were treated by TNCF (THP-doxorubicin, vinorelbine, cyclophosphamide, fluorouracil, D1 to D4) with CSF support: 11 patients received GM-CSF (D5 to D14); 16 patients G-CSF (D5 to D14) and 16 patients GM-CSF (D5-D14) plus G-CSF (D10-D14). Between two subsequent cycles, progenitor cells were assessed daily, from D13 to D17. The WBC count was similar for patients receiving G-CSF alone or GM-CSF plus G-CSF, but significantly greater than that of patients receiving GM-CSF alone (P<0.001). The GM-CSF plus G-CSF combination led to better PBPC mobilization, with significantly different kinetics (P<0.001) and optimal mean values of CFU-GM, CD34+ cells and cells in cycle, at D15 compared to those obtained with G-CSF or GM-CSF alone. The significantly greater PBPC mobilization obtained with a CSF combination by D15 could be of value for PBPC collection and therapeutic reinjection after high-dose chemotherapies.
Collapse
Affiliation(s)
- S Charrier
- Centre de Lutte Régionale contre le Cancer Jean Perrin, Clermont-Ferrand, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Abstract
The encapsulation of liquid cheese aroma (20%) in different carbohydrate matrices by spray-drying was investigated. Carbohydrate stabilized emulsions have been prepared by two emulsifying methods, ultrasonic or Ultra-Turrax treatments, and have been compared in terms of emulsion stability and encapsulation efficiency. The use of ultrasound is particularly effective to obtain a stable emulsion with maltodextrin as support, which is known for poor emulsification properties. In the same way, the spray-dried maltodextrin microcapsules were more effective for retaining cheese aroma when ultrasound (12.7 g/100 g of dry powder) was used for the emulsification step rather than Ultra-Turrax (10.7 g/100 g of dry powder). In terms of encapsulation efficiency, the best system of cheese aroma encapsulation is obtained using ultrasound for the emulsification step and modified starch as support (94.3%). With this support, the positive effect of ultrasound resulted in a lower microcaspsule size and in a higher aroma retention than when Ultra-Turrax was used (83.3%). Studies on the aroma profiles showed changes after encapsulation that depend not only on the nature of the support and the emulsification method but also on the interactions between the aroma compound and the matrix. In terms of flavor quality, the best system of cheese aroma encapsulation is obtained using ultrasound and maltodextrin as support.
Collapse
Affiliation(s)
- N Mongenot
- Departement Génie Biologique et Sciences des Aliments, Unité de Microbiologie et Biochimie Industrielles, Université de Montpellier 2, 34095 Montpellier Cedex 05, France
| | | | | |
Collapse
|
8
|
Le Bouëdec G, Charrier S, Curé H, Peffault de Latour M, Ferrière JP, Chollet P, Dauplat J. [Neoadjuvant chemotherapy of breast cancer. Role of surgery in cases of complete clinical response]. Presse Med 1999; 28:2145-8. [PMID: 10629689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/15/2023] Open
Abstract
OBJECTIVES Assess the importance of systematic surgical exploration of the tumor focus in case of complete clinical response to neoadjuvant chemotherapy for operable breast cancer. PATIENTS AND METHODS Between 1985 and 1997, first intention chemotherapy (4 to 6 cures) was given to 433 breast cancer patients with resectable tumors measuring > or = 3 cm but who required mammectomy. Complete clinical response was observed in 112 patients (26%); 31 of them had normal mammography and ultrasound examinations (7%). Local treatment in this favorable context varied: 82 patients underwent surgery (71 conservative procedures, 11 radical procedures) and 30 patients received radiation therapy alone. RESULTS Complete histological response was obtained in 22 cases accounting for 6% of the entire series, 27% of the complete clinical responses, and 45% of the complete clinical and imaging responses. The incidence of local recurrence at a mean 107 month follow-up was compared between patients given complementary surgical or radiation therapy after complete clinical response. Recurrence was observed in 10 of the 82 operated patients versus 8 of the 30 nonoperated patients (12% versus 27%, NS). CONCLUSION Complete clinical response after neoadjuvant chemotherapy does not rule out the need for surgical resection of the tumor focus because the risk of neoplastic reliquats remains high (3 out of 4 cases) and because the surgical specimen provides important histological information for prognosis (in vivo chemosensitivity test). lumpectomy also contributes to reducing the risk of local recurrence.
Collapse
Affiliation(s)
- G Le Bouëdec
- Centre Régional de Lutte Contre le Cancer Jean Perrin, Clermont-Ferrand
| | | | | | | | | | | | | |
Collapse
|
9
|
Kwiatkowski F, Gachon F, Charrier S, Sancho-garnier H, Kramar A. [Decision making in biology: ROC analysis]. Bull Cancer 1999; 86:787-9. [PMID: 10576816] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Affiliation(s)
- F Kwiatkowski
- Service statistique, Centre Jean-Parrin, Clermont-Ferrand
| | | | | | | | | |
Collapse
|
10
|
Charrier S, Chassagne J, Curé H, Bay JO, Communal Y, Portefaix G, Ferrière JP, Bétail G, Plagne R, Chollet P. Mobilization of peripheral blood progenitor cells after induction chemotherapy (THP-doxorubicin-vinorelbine-cyclophosphamide-fluorouracil) and granulocyte colony-stimulating factor in breast cancer. Bone Marrow Transplant 1998; 22:845-51. [PMID: 9827811 DOI: 10.1038/sj.bmt.1701465] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
In order to evaluate the mobilization of peripheral blood progenitor cells (PBPC) after an effective induction regimen in breast cancer, we performed a study on 15 breast cancer patients. Between January 1995 and June 1996, these patients received TNCF (THP-doxorubicin. vinorelbine, cyclophosphamide, fluorouracil for four days, every 21 days) with G-CSF support (5 microg/kg for 10 days after chemotherapy) to reduce aplasia. This regimen is known to result in a complete pathological response in 30% of patients. Between two cycles of TNCF treatment, hematological recovery was observed. Progenitor cells (CFU-GM and CD34+ cells) and mononuclear cells in DNA synthesis (MCDS) counts were performed daily, between the 12th and 17th post-chemotherapy days (81 samples). The results showed a similarity for hematological recovery and PBPC mobilization kinetics depending on the number of treatment cycles. The three methods used for PBPC evaluation were well correlated (P < 0.01) with an optimal mean PBPC recruitment by the last day of G-CSF administration: respectively, 11 520 (1729-26539) CFU-GM/ml of blood, 249 (14-1160) CD34+ cells/microl of blood and 211 (21-554) MCDS/microl of blood. These results suggested that a daily injection of G-CSF after one or two TNCF cycles will produce an effective PBPC mobilization in comparison with currently used regimens.
Collapse
Affiliation(s)
- S Charrier
- Centre Jean Perrin and INSERM U484, Clermont-Ferrand, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Gachon F, Charrier S, Kwiatkowski F, Besse G, Curé H, Chassagne J, Ferrière J, Penault-Llorca F, Dauplat J, Chollet P. Expression of cytosolic thymidine kinase in the proliferative breast carcinoma after primary chemotherapy: Therapeutic indication. Eur J Cancer 1998. [DOI: 10.1016/s0959-8049(98)80425-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Laurichesse H, Tauveron I, Gourdon F, Cormerais L, Champredon C, Charrier S, Rochon C, Lamain S, Bayle G, Laveran H, Thieblot P, Beytout J, Grizard J. Threonine and methionine are limiting amino acids for protein synthesis in patients with AIDS. J Nutr 1998; 128:1342-8. [PMID: 9687554 DOI: 10.1093/jn/128.8.1342] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
This study was conducted to identify the most rate-limiting amino acids for whole-body protein synthesis in acquired immunodeficiency syndrome (AIDS) patients. We postulated that an essential amino acid that would be rate limiting in AIDS should have a low basal plasma concentration and should remain at a low level during amino acid infusion. Seven male AIDS patients (median age 37 y, CD4 cell count: 76 mm-3) without any clinically active opportunistic infection during the month before the experiment were infused intravenously with a complete amino acid-glucose mixture for 2.5 h. Eight healthy volunteers were used as controls. Before the infusion, the concentrations of most free essential amino acids (methionine, threonine, histidine, isoleucine, leucine and tryptophan) were significantly lower (P < 0.05) in AIDS patients than in controls. Most plasma free essential amino acids increased significantly during infusion. However, the absolute increase above basal levels for threonine, valine, lysine, (P < 0.05) and methionine (P < 0.073) was smaller in AIDS patients than in control subjects. Thus, threonine and possibly methionine may be rate limiting for whole-body protein synthesis in AIDS patients, suggesting that there are selective amino acid requirements in patients with AIDS.
Collapse
Affiliation(s)
- H Laurichesse
- Service des Maladies Infectieuses et Tropicales, 63003 Clermont-Ferrand, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Ferrière JP, Assier I, Curé H, Charrier S, Kwiatkowski F, Achard JL, Dauplat J, Chollet P. Primary chemotherapy in breast cancer: correlation between tumor response and patient outcome. Am J Clin Oncol 1998; 21:117-20. [PMID: 9537193 DOI: 10.1097/00000421-199804000-00003] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
This study focused on the correlation between tumor response and patient outcome in 329 breast cancers treated with primary chemotherapy. There were 141 stage IIIB tumors, including 109 inflammatory carcinomas. Other malignancies (34 IIIA, 99 IIB, 55 IIA) were operable but considered to be too large (> 3 cm) for conservative surgery and received primary chemotherapy to avoid mastectomy. All received the AVCF regimen, comprising 4-week cycles of doxorubicin (30 mg/m2) day 1, vincristine (1 mg/m2) day 1, 5-fluorouracil (5-FU; 400 mg/m2) days 2 through 5, cyclophosphamide (300 mg/m2) days 2 through 5. In 189 cases, methotrexate (15 mg/m2) was added at day 2 and day 3. Patients received 6 cycles, then underwent locoregional treatment (surgery, radiotherapy, or both) according to tumor regression. The response rate was assessed by clinical, mammographic, and echographic examinations: a 50% rate of objective responses were noted, of which 15% were complete responses (tumor shrinkage allowed breast conservation in 68% of patients who had stages II or IIIA). For the whole population studied, median follow-up was 111 months (range, 60- 196). One hundred fifty-seven patients had disease relapse (48 local, 14 contralateral, 95 distant). Kaplan-Meier estimates showed an increased 10-year overall survival for patients in complete response, as compared with noncomplete response: 70% versus 50% (p < 0.03). Complete response to neoadjuvant chemotherapy seems a good prognostic factor.
Collapse
|
14
|
Ferrière JP, Charrier S, Curé H, Kwiatkowski F, Courtadon M, Bélembaogo E, de Latour M, Achard JL, Dauplat J, Chollet P. Adjuvant chemotherapy with doxorubicin-containing regimen for 326 stage II breast cancers: 15-year results. Am J Clin Oncol 1997; 20:219-25. [PMID: 9167740 DOI: 10.1097/00000421-199706000-00001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Between 1975 and 1986, 326 patients with stage II breast cancer were treated with an adjuvant combination of doxorubicin, vincristine, cyclophosphamide, and 5-fluorouracil (AVCF) following regional therapy (232 modified radical mastectomy, 94 lumpectomies, 304 irradiations). The AVCF regimen consisted of 4-week cycles of doxorubicin (30 mg/m2 day 1, modified radical mastectomy), vincristine (1 mg/m2 day 2), 5-fluorouracil 400 (mg/m2), and cyclophosphamide (300 mg/m2) days 3-6. Two hundred twenty-four patients (pts) had six cycles and 102 pts 12 cycles; 90 pts also received 30 mg daily tamoxifen for 1 year after chemotherapy. As of March 1994, the median follow-up was 130 months (range 86-221). One hundred eighteen pts developed recurrences (7 local, 19 controlateral, 92 metastatic) and 104 died. Estimated disease-free survival (DFS) was 5 years, 76 +/- 5%; 10 years, 64 +/- 5%; 15 years, 54 +/- 9%. Overall survival (OS) was 5 years, 85 +/- 4%; 10 years, 70 +/- 5%; 15 years, 58 +/- 10%. Survival was affected by the number of involved lymph nodes (258 pts were N+), menopausal status (OS at 15 years: 53% for MP+ and 65% for MP-) and Scarff-Bloom-Richardson grading, but not by hormonal receptors, number of courses, or associated hormonotherapy. Minimal cardiac toxicity was induced by doxorubicin either during or subsequent to treatment completion.
Collapse
Affiliation(s)
- J P Ferrière
- Centre Jean Perrin and Inserm, Clermont-Ferrand, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Chollet P, Charrier S, Brain E, Curé H, van Praagh I, Feillel V, de Latour M, Dauplat J, Misset JL, Ferrière JP. Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer 1997; 33:862-6. [PMID: 9291806 DOI: 10.1016/s0959-8049(97)00038-5] [Citation(s) in RCA: 81] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Neoadjuvant chemotherapy is used to improve patients' survival in locally-advanced and inflammatory breast cancer and to increase conservative surgical procedures in bulky tumours. Pathological complete responses are unusual. The aim of this pilot study was to assess the clinical and pathological response rates and to evaluate toxicity with a new protocol of primary chemotherapy in 50 high-risk breast cancer patients. All tumours were > 3 cm and had at least one other adverse prognostic factor: lymph node involvement (32 N1, 6 N2), SBR grade III (20), aneuploidy (29), negative hormonal receptors (19). Patients were treated by 3-week cycles of THP-doxorubicin 20 mg/m2 D1 to 3, vinorelbine 25 mg/m2 D1 and 4, cyclophosphamide 300 mg/m2 and 5-fluorouracil 400 mg/m2 D1 to 4 (TNCF). 38 patients received G-CSF or GM-CSF support. After 4-6 cycles, all underwent surgery (39 conservative, 11 modified radical). Tumour response was assessed clinically, by mammography and echography and on pathological specimens. An objective clinical response was observed for 43 patients: 26 complete (51%) and 18 partial (37%). After pathological review, 11 patients (22%) were devoid of any tumour cells, 4 others (8%) had only in situ carcinoma. From 253 evaluated cycles, grade III-IV toxicity occurred, 81% with neutropenia, 25% with anaemia, and 20% with thrombocytopenia. All patients recovered. This regimen induced a severe but not life-threatening haematological toxicity and resulted in a high pathological response rate (30%).
Collapse
Affiliation(s)
- P Chollet
- Centre Jean Perrin, Clermont-Ferrand, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Cure H, Charrier S, Ferrière JP, Van Praagh I, Assier I, Feillel V, De Latour M, Bay JO, Achard JL, Dauplat J, Chollet P. [First-line chemotherapy in operable breast neoplasms: results of 3 protocols]. Bull Cancer 1997; 84:31-4. [PMID: 9180856] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
In order to avoid modified radical mastectomy, a neoadjuvant approach was adopted in our institute for operable bulky breast cancers. From January, 1982, to December, 1995, 288 patients received primary chemotherapy with 3 different regimens (all doses mg/m2): (1) AVCF/AVCFM, 167 patients (adriamycin 30, vincristine 1 d1, cyclophosphamide 300, fluorouracil 400 d2-d5 and methotrexate 20 d2 and d4, every 28 days); (2) NEM, 78 patients (vinorelbine 25, epirubicin 35, methotrexate 20 d1 and d8, every 28 days); and (3) TNCF, 43 patients (THP-adria 20, d1-d3, vinorelbine 25 d1 and d4, cyclophosphamide 300, fluorouracil 400 d1-d4, every 21 days). Evaluation of the response comprised 3 methods: clinical (C), echographic (E), mammographic (M). The overall objective response rate (C: 63/90/93; E: 49/61/85; M: 53/65/83%) is higher with regimens (2) and (3). The complete response rate was increased 2-fold with TNCF but the hematologic toxicity was very superior with this combination. Patients were all operated for (2) and (3), only several for (1), and the breast conservation rate (68/83/79%) was quite similar in the 3 regimens. The pathological complete response rate reached 23% with TNCF. However the impact on patient survival has to be confirmed.
Collapse
Affiliation(s)
- H Cure
- Centre Jean-Perrin, INSERM U. 71, Clermont-Ferrand, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Maublant J, de Latour M, Mestas D, Clemenson A, Charrier S, Feillel V, Le Bouedec G, Kaufmann P, Dauplat J, Veyre A. Technetium-99m-sestamibi uptake in breast tumor and associated lymph nodes. J Nucl Med 1996; 37:922-5. [PMID: 8683312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
UNLABELLED The aim of this study was to measure the accumulation of 99mTc-sestamibi in breast tumors and their axillary lymph nodes in patients undergoing scintimammography. METHODS Eighteen patients who were scheduled for breast surgery underwent scintimammography with 740 MBq of 99mTc-sestamibi on the day before the operation. The next morning, reinjection with 370 MBq was performed. Immediately after the surgical procedure, the 99mTc activity of the tumor samples and, when available, the related lymph nodes was measured in a gamma counter. The samples were weighed and prepared for histological analysis. The activity of each sample was normalized to the mean activity of normal tissue samples obtained from the same patient. RESULTS Among the 198 samples analyzed, the relative uptake of sestamibi was increased in 111 containing normal lymph nodes (1.80+/-0.79 vs 1.00+/-0.22, p<0.05), as well as in the seven containing invaded lymph nodes (2.01+/-0.83, p<0.01) and more dramatically, in the 22 with a carcinoma (5.64+/-3.06, p<0.001). In two patients with a benign lesion, both scintigraphy and counting demonstrated increased activity in the tumor. Four patients had negative scan results despite the presence of malignant tumor and a more than fourfold increase of sestamibi concentration in two of them. CONCLUSION Technetium-99m-sestamibi concentrates strongly in breast carcinoma, sometimes even when the scan results appear normal, and mildly in lymph nodes, especially when invaded; it also concentrates in some benign tumors, possibly in relation to the presence of epithelial hyperplasia.
Collapse
Affiliation(s)
- J Maublant
- Department of Nuclear Medicine, Centre Jean Perrin, Faculty of Medicine, Clermont-Ferrand, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Charrier S, Achard J, Auvray H, Ferriere J, Courtadon M, Chollet P. PP-5-7 Interest of irradiation and AVCF chemotherapy in 241 Node-positive stage ii breast cancers: Late results. Eur J Cancer 1996. [DOI: 10.1016/0959-8049(96)84170-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
19
|
van Praagh I, Ferrière J, Curé H, Feillel V, Le Bouëdec G, de Latour M, Rolhion C, Charrier S, Assier I, Misset J, Dauplat J, Chollet P. 53 Comparison of 3 neoadjuvant chemotherapy regimens for operable breast cancer. Eur J Cancer 1995. [DOI: 10.1016/0959-8049(95)95305-p] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
20
|
Tauveron I, Charrier S, Champredon C, Bonnet Y, Berry C, Bayle G, Prugnaud J, Obled C, Grizard J, Thiéblot P. Response of leucine metabolism to hyperinsulinemia under amino acid replacement in experimental hyperthyroidism. Am J Physiol 1995; 269:E499-507. [PMID: 7573427 DOI: 10.1152/ajpendo.1995.269.3.e499] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
We investigated the responsiveness of protein metabolism to insulin as a mediator of the protein catabolic response to hyperthyroidism in humans. Six healthy volunteers were studied in a postabsorptive state before and after oral intake of thyroid hormones (2 micrograms.kg-1.day-1 L-thyroxine for 6 wk along with 1 microgram.kg-1.day-1 triiodothyronine for the last 2 wk). Insulin was infused at 7.14 nmol.kg-1.min-1 for 140 min under euglycemic and eukalemic clamps. An appropriate amino acid infusion was used to blunt insulin-induced hypoaminoacidemia. Leucine kinetics were assessed using a primed continuous infusion of L-[1-13C]leucine. Hyperthyroidism induced a significant increase (P < 0.05) in leucine endogenous appearance rate (a reflection of proteolysis; 2.15 +/- 0.06 vs. 1.76 +/- 0.03 mumol.kg-1.min-1 in the control state), oxidation (0.54 +/- 0.04 vs. 0.47 +/- 0.07), and nonoxidative disposal (a reflection of protein synthesis; 1.80 +/- 0.06 vs. 1.45 +/- 0.06). Insulin lowered proteolysis. Further hyperthyroidism improved the ability of insulin to inhibit proteolysis, whether considered as an absolute decrease (-0.57 +/- 0.02 vs. -0.45 +/- 0.05 mumol.kg-1.min-1, P < 0.05) or related to insulinemia [1.59 +/- 0.11 vs. 1.01 +/- 0.08 mumol leucine.kg-1.min-1/(nmol insulin/l), P < 0.05]. Insulin also moderately (but significantly P < 0.05) lowered protein synthesis in both control and hyperthyroid states. These changes in insulin action may provide a mechanism to save body protein during hyperthyroidism.
Collapse
Affiliation(s)
- I Tauveron
- Laboratoire d'Etude du Métabolisme Azoté, Institut National de la Recherche Agronomique, Centre de Clermont-Ferrand, Saint-Genès Champanelle, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|